中硼医疗已领先一步，在2017年自主研制了BPA成对诊断药物18F-BPA，并在科技部国家重点研发计划的支持下，由北京协和医院核医学科霍力教授和李方教授主持开展了人体研究，充分验证了18F-BPA-PET在BNCT中的重要作用。中硼医疗与东诚药业合作，依托东诚安迪科强大的核药生产与配送网络优势，为18F-BPA药物未来...
日前，日本硼中子俘获治疗（下称BNCT）主要研究机构大阪医科大学宣布将开展一项由研究者发起的针对复发性脑胶质瘤的临床研究。该研究将纳入标准治疗后复发的恶性脑胶质瘤患者，旨在通过18F-BPA-PET影像技术，完善BNCT后疗效观察及预后评价，以便更准确地评估BNCT治疗复发性脑胶质瘤的有效性。18F-BPA-PET检测技术示意图 ...
因此,本次开展的研究将探索利用18F-BPA-PET检测新技术更准确地评估BNCT在复发性脑胶质瘤中的疗效。 中硼医疗研究人员表示,18F-BPA是BPA的成对诊断药物,二者在人体内生物学特性基本相似,由于18F核素发射的射线能够被PET/CT探测到,并形成影像,因此临床使用18F-BPA PET/CT图像在BNCT治疗前观察体内药物摄取情况,可用于...
18F-BPA PETradiation absorbed doseeffective doseBackground: Boron neutron capture therapy (BNCT) is a molecular radiation therapy approach based on the B-10 (n, alpha) 7 Li nuclear reaction in cancer cells. In BNCT, delivery of B-10 in the form of 4-borono-phenylalanine conjugated with ...
18F-boronophenylalanine (18F-BPA)objective response rate (ORR)positron emission tomography (PET)tumor to normal tissue ratio (T/N ratio)Background: Boron neutron capture therapy (BNCT) stands out as a propitious anti-cancer modality. 18F-boronophenylalanine positron emission tomography (BPA-PET) ...
Results: The patient characteristics and the 18F-BPA PET values are shown in Table 1. SUVmax of SCC and STS showed a gradual decrease, but the decrease was statistically significant only between 30 and 120 min. No significant TNR changes of 18F-FBPA were seen in SCC and STS. Conclusions:...